TITLE

Business Briefs

PUB. DATE
April 2012
SOURCE
Transplant News;Apr2012, Vol. 22 Issue 4, p9
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to health care industry. The Total Artificial Heart (TAH) of SynCardia Systems Inc. has received a Humanitarian Use Device (HUD) designation from the U.S. Food and Drug Administration (FDA) for destination therapy (DT). Jarvik Heart Inc. was given an approval by the FDA for the Pivotal Trial of its Jarvik 2000 heart for DT. IntelliCeli BioSciences will be transferring into a new site to address the issues on its manufacturing practice mentioned by the FDA.
ACCESSION #
76173133

 

Related Articles

  • Jarvik Heart gets full approval from the FDA to conduct destination trial for the Jarvik 2000.  // Transplant News;Aug2012, Vol. 22 Issue 8, p6 

    The article reports that the FDA has given full approval of its Pivotal Trial for evaluation of the Jarvik 2000 heart for destination therapy (DT).

  • Business Briefs.  // Transplant News;Mar2013, Vol. 23 Issue 3, p7 

    The article offers business news briefs as of March 2013. The Red Cross Blood Transfusion Service of Upper Austria has been accredited by the European Federation for Immunogenetics (EFI). An exercise program helped a set of lung transplant patients in Belgium, to improve their quality of health...

  • Business Briefs.  // Transplant News;Aug2011, Vol. 21 Issue 8, p7 

    The article offers news briefs related to transplantation in the U.S. It says that Mesoblast Ltd. has been approved by the U.S. Food and Drug Administration (FDA) to start a Phase 3 clinical trial for bone marrow regeneration in patients with blood cancer. It mentions the regional collaboration...

  • FDA approves topical anesthetic cream.  // Dermatology Times;Jan2013, Vol. 34 Issue 1, p12 

    The article reports the approval by the Food and Drug Administration for a supplemental new drug application for a topical local anesthetic cream in superficial cosmetic procedures.

  • FDA approves Argus II Retinal Prosthesis System; device hailed as first bionic eye.  // Transplant News;Feb2013, Vol. 23 Issue 2, p10 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on the Second Sight Medical Products Inc.'s Argus II Retinal Prosthesis System, a device which combines computer and small video camera on eyeglass and an artificial retina implanted in the eye.

  • Tarix receives FDA Orphan Drug designation for stem cell engraftment drug TXA127.  // Transplant News;Jul2010, Vol. 20 Issue 7, p10 

    The article announces the drug TXA127 from Tarix Pharmaceuticals in Brookline, Massachusetts that has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for a treatment to improve the engraftment in patients having a stem cell transplant.

  • Santarus Is 1st S.D. Firm to Earn FDA OK in '06. Weeks, Katie // San Diego Business Journal;3/6/2006, Vol. 27 Issue 10, p12 

    The article reports on developments related to business in San Diego, California. Santarus Inc. has won the approval for the drug Zegerid from the U.S. Food and Drug Administration. Acon Laboratories Inc. has resolved a nearly three-year patent infringement lawsuit filed against Iverness Medical...

  • Breast Cancer Update.  // PharmaWatch: Cancer;May2008, Vol. 7 Issue 5, p8 

    The article reports development related to breast cancer. Abraxis BioScience Inc. has partnered with Taiho Pharmaceutical Co. Ltd. to market Abraxane as injectable suspension for the treatment of breast cancer. Pro-Pharmaceuticals Inc. has received an approval from the U.S. Food and Drug...

  • FDA OKs Lymphoseek for lymph node mapping.  // Dermatology Times;Apr 2013, Vol. 34 Issue 4, p12 

    The article reports that Lymphoseek, a radioactive diagnostic imaging agent which can map lymph nodes in patients with certain cancers has been approved by the Food and Drug Administration (FDA).

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics